Medication Affordability Act (S. 2658)

Summary

Makes drug companies certify that information they give to the FDA and the U.S. Patent Office for drug patents is the same and complete.

What problem does this solve?

Drug companies may provide different information to the FDA and the Patent Office to unfairly extend their monopolies. This bill requires them to share consistent information with both agencies to prevent this.

What does this bill do?

Requires consistent information between FDA and Patent Office

Forces drug makers to certify that the information they submit to the FDA and the U.S. Patent and Trademark Office (USPTO) is consistent for anything important to getting a patent.

Creates a new defense against patent lawsuits

Allows a company sued for patent infringement to defend itself by proving the patent owner failed to share required information between the FDA and USPTO.

Covers both traditional drugs and biologic medicines

Applies the new certification and information sharing rules to applications for both standard chemical drugs and more complex biological products.

Protects trade secrets

Ensures that any secret business information shared with the USPTO under this act receives the same protections it would at the FDA.

Who does this affect?

Pharmaceutical companies
Generic drug manufacturers
Patients requiring prescription medication

What is the real world impact?

•

Promotes faster generic drug availability

Forces drug makers to be honest about their patents with both the FDA and the Patent Office. This can stop them from getting weak patents that block cheaper generic drugs from coming to market.

•

Creates new legal challenges for patents

Gives generic drug makers a new way to fight patent lawsuits. They can argue a brand-name drug's patent is invalid if the company didn't share information correctly between government agencies.

When does this start?

The new rules apply to all drug applications submitted after this bill becomes law, with special rules for older applications.

New drug applications

Applies to any original drug or biologic application submitted on or after the date the bill becomes law.

Existing drug applications

For applications submitted before the law is passed, the rules only apply to patents issued after the law's enactment date.

Existing patents on older drugs

For patents issued before the law is passed, the rules only apply to new communications with the FDA or USPTO made after the law's enactment date.